Compounded GLP-1 Drugs: Safety Questions and Red Flags

If you've looked into GLP-1 treatment, you've probably seen compounded semaglutide or tirzepatide offered by clinics or telehealth sites, often for much less than the brand-name price. Cost and access are real problems, so it's worth understanding what these products are, what's changed and which red flags matter. This article covers the US situation as of October 2026.

What is a compounded drug?

Compounding means a pharmacy prepares a medicine for a patient, usually to meet a specific need an approved product can't, such as an allergy to an ingredient. Compounded drugs are not FDA-approved: the FDA doesn't review their safety, effectiveness or quality before they're sold. They're also not the same as generics, which are FDA-approved copies. As of October 2026, there is no FDA-approved generic of semaglutide or tirzepatide in the US.

What's changed since the shortages?

During the brand-name shortages, federal rules gave compounders more room to make copies. That period is over. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and the temporary grace periods for compounders ended during 2025. In an April 2026 update, the FDA reminded compounders that neither drug is on the shortage list, that pharmacies shouldn't regularly make essentially copies of approved drugs, and that larger outsourcing facilities can't currently make them from bulk ingredients.

The FDA has also cracked down on marketing. In March 2026 it sent warning letters to 30 telehealth companies over false or misleading claims about compounded GLP-1s, and more letters followed in June 2026.

What has the FDA warned about?

• Adverse events: as of May 31, 2026, the FDA had received 990 adverse-event reports linked to compounded semaglutide and more than 730 linked to compounded tirzepatide, and says the true number is likely higher because many pharmacies aren't required to report.
• Dosing errors: some people have accidentally taken 5 to 20 times their intended dose, often when drawing doses from multidose vials with syringes. Confusion between milligrams, milliliters and "units," different concentrations between pharmacies, and miscalculations by prescribers have all played a part. Some people needed hospital care.
• Salt forms: some products use semaglutide sodium or semaglutide acetate, which are different active ingredients from the one in approved products. The FDA says it isn't aware of any lawful basis for using them in compounding.
• Counterfeits: fake Ozempic has been found in the US supply chain, which may contain the wrong ingredient or the wrong amount.

Red flags from a seller

The FDA lists marketing claims it considers false or misleading. Be cautious if a seller:

• calls a compounded product "generic Ozempic," "generic Mounjaro" or "the same as" a brand-name drug
• says it's FDA-approved or clinically proven to give the same results
• claims it comes from an "FDA-approved pharmacy" (the FDA doesn't approve pharmacies)
• puts its own brand name on the drug without making clear who actually compounded it
• doesn't require a real prescription or a proper clinical assessment
• sells peptides labeled "for research use only," or offers to ship investigational drugs

What can you do?

Ask your prescriber and pharmacist exactly what you're getting: the active ingredient (including any salt form), which pharmacy made it, its concentration, your dose in milligrams, which syringe to use, and how to store it. Ask, too, whether an FDA-approved product, savings program or generic alternative could meet your needs; our guide to GLP-1 treatment costs covers some of those questions. The FDA's BeSafeRx program explains how to check that an online pharmacy is licensed.

If you think you've taken too much, contact your prescriber or call Poison Help (1-800-222-1222 in the US). Seek urgent care for severe or persistent abdominal pain (especially if it spreads to your back), vomiting you can't stop, signs of dehydration such as dizziness or very little urine, or fainting.

The takeaway

Affordability is a genuine barrier, and wanting a cheaper option makes total sense. But a lower price or fast shipping isn't proof of quality. Knowing exactly what's in the vial, who made it and how to measure it matters as much as the medicine itself. And if you spot a too-good-to-be-true offer on social media, here are more red flags in viral GLP-1 tips.